Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is mainly expressed in the liver but can also be found in the intestine and kidneys. PCSK9 promotes the degradation of low density lipoprotein receptors (LDLR) by reducing their recycling and targeting the receptors for...

Full description

Bibliographic Details
Main Authors: Constantine E Kosmas, Eddy DeJesus, Rosmery Morcelo, Frank Garcia, Peter D Montan, Eliscer Guzman
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2017-11-01
Series:Drugs in Context
Subjects:
AT04A vaccine
low density lipoprotein cholesterol
LDL-C
low density lipoprotein receptors
LDLR
proprotein convertase subtilisin/kexin type 9
PCSK9
small interfering RNA
siRNA
Online Access:http://www.drugsincontext.com/lipid-lowering-interventions-targeting-proprotein-convertase-subtilisinkexin-type-9-pcsk9-an-emerging-chapter-in-lipid-lowering-therapy/

Internet

http://www.drugsincontext.com/lipid-lowering-interventions-targeting-proprotein-convertase-subtilisinkexin-type-9-pcsk9-an-emerging-chapter-in-lipid-lowering-therapy/

Similar Items